K2M has received 510(k) clearance from the US Food and Drug Administration (FDA) to expand its Cascadia lateral interbody system, featuring the company’s Lamellar 3D titanium technology.
K2M’s Lamellar 3D titanium technology uses a 3D printing method to create structures that are impossible with traditional manufacturing techniques. Starting with a titanium powder, the Cascadia implants are grown through the selective application of a high-energy laser beam, incorporating complex internal geometries and rough surface architecture that pre-clinical data have associated with bone growth activity.
The technology is designed to incorporates a porous structure along with rough surfaces to allow the potential for bony integration throughout the implant. The Cascadia interbody devices utilise this technology to create a 70% porous implant with an increased bone graft volume and similar stiffness when compared to K2M PEEK designs.
“Cascadia is an exciting innovation for lateral spine fusions,” states Greg T Poulter, an orthopedic spine surgeon at OrthoIndy (Indianapolis, USA). “The unique engineering and 3D printing allows the implant to have the biocompatibility and ongrowth characteristics of titanium, while allowing [for] stiffness that more closely matches bone. The graft volume and surface area for fusion are generous and the new size options for lordosis allow me to address each patient’s individual sagittal plane requirements.”
